C.D.C. Tells States How to Prepare for Covid-19 Vaccine by Early November
As Trump pushes the possibility of a vaccine this year, the C.D.C. has outlined technical scenarios to state public health officials for an unidentified “Vaccine A” and “Vaccine B.”
A volunteer received an experimental coronavirus vaccine made by Moderna Therapeutics in Detroit last month.
A volunteer received an experimental coronavirus vaccine made by Moderna Therapeutics in Detroit last month.Credit…Henry Ford Health System/Agence France-Presse — Getty Images
By Sheila Kaplan, Katherine J. Wu and Katie Thomas
Sept. 2, 2020, 2:34 p.m. ET
The Centers for Disease Control and Prevention has notified public health officials in all 50 states and five large cities to prepare to distribute a coronavirus vaccine to health care workers and other high-risk groups as soon as late October or early November.
The new C.D.C. guidance is the latest sign of an accelerating race for a vaccine to greatly ease a pandemic that has killed more than 184,000 Americans. The documents were sent out on the same day that President Trump told the nation in his speech to the Republican National Convention that a vaccine might arrive before the end of the year.
Over the past week, both Dr. Anthony S. Fauci, the country’s top infectious disease expert, and Dr. Stephen Hahn, who heads the Food and Drug Administration, have said in interviews with news organizations that a vaccine could be available for certain groups before clinical trials have been completed, if the data is overwhelmingly positive.
Public health experts agree that agencies at all levels of government should urgently prepare for what will eventually be a vast, complex effort to vaccinate hundreds of millions of Americans. But the possibility of a rollout in late October or early November has also heightened concerns that the Trump administration is seeking to rush the distribution of a vaccine — or simply to hype that one is possible — before Election Day on Nov. 3.
The C.D.C. plans lay out technical specifications for two candidates described as “Vaccine A” and “Vaccine B,” including requirements for shipping, mixing, storage and administration. The details seem to match the products developed by Pfizer and Moderna, which are the furthest along in late-stage clinical trials. On Aug. 20, Pfizer said it was “on track” for seeking government review “as early as October 2020.”
“This timeline of the initial deployment at the end of October is deeply worrisome for the politicization of public health and the potential safety ramifications,” said Saskia Popescu, an infection prevention epidemiologist based in Arizona. “It’s hard not to see this as a push for a pre-election vaccine.”
Three documents were sent to public health officials in all states and territories as well as New York, Chicago, Philadelphia, Houston and San Antonio on Aug. 27. They outlined detailed scenarios for distributing two unidentified vaccine candidates, each requiring two doses a few weeks apart, at hospitals, mobile clinics and other facilities offering easy access to the first targeted recipients.
The guidance noted that health care professionals, including long-term care employees, would be among the first to receive the product, along with other essential workers and national security employees. People 65 or older, as well as those from “racial and ethnic minority populations,” Native Americans and incarcerated individuals — all communities known to be at greater risk of contracting the virus and experiencing severe disease — were also prioritized in the documents.
That’s a positive development, “so it doesn’t just all wind up in high-income, affluent suburbs,” said Dr. Cedric Dark, an emergency medicine physician at Baylor College of Medicine in Texas.
Latest Updates: The Coronavirus Outbreak
Updated 2h ago
C.D.C. tells health officials to be ready to distribute a vaccine by November, raising concerns over politicized timing.
The first death tied to the Sturgis Motorcycle Rally is reported in Minnesota.
New studies show inexpensive steroid drugs can help critically sick people survive Covid-19.
More live coverage: Markets
The C.D.C. noted in its guidance that “limited Covid -19 vaccine doses may be available by early November 2020.” The documents were dispatched the same day that Dr. Robert Redfield, director of the C.D.C., sent a letter to governors asking them to ready vaccine distribution sites by Nov. 1, as McClatchy reported.
Coronavirus Schools Briefing: The pandemic is upending education. Get the latest news and tips as students go back to school.
The agency also said its plans were as yet hypothetical, noting, “The Covid-19 vaccine landscape is evolving and uncertain, and these scenarios may evolve as more information is available.” A C.D.C. spokeswoman confirmed that the documents were sent but declined to comment further.
Many of the details listed for the two vaccines — including required storage temperature, the number of days needed between doses, and the type of medical center that can accommodate the product’s storage — match what Pfizer and Moderna have said about their products, which are based on so-called mRNA technology. Neither company responded to requests for comment.
The scenarios, which assume that the two vaccines could demonstrate sufficient safety and effectiveness for an emergency authorization from the F.D.A. by the end of October, note that Vaccine A, which seems to match Pfizer’s, would have about two million doses ready within this time frame, and that Vaccine B, whose description matches Moderna’s, would have about one million doses ready, with tens of millions of doses of each vaccine ready by the end of the year. Although it’s possible that some promising preliminary data could emerge by the end of October, experts are skeptical.
“The timeline that’s reported seems a bit ambitious to me,” Dr. Dark said. “October’s like 30 days away.”
Trials that test a vaccine’s effectiveness can take years to yield reliable results. It’s possible to draw conclusions sooner “if there is an overwhelming effect” in which vaccinated people appear to be far better protected from disease, said Padmini Pillai, a vaccine researcher and immunologist at M.I.T. But data gathered early in a trial might not hold true months down the line. And researchers need time to test large numbers of people from a variety of backgrounds to determine how well the vaccine works in different populations — including the vulnerable communities identified in the guidelines.
Should any of these snags occur, Dr. Pillai said, “all of this together could diminish public trust in the vaccine.”
Me: I wrote the CDC and told them to try my salt water cure on Coronavirus – before it becomes Covid-19 and that I had been doing it for over 25 years and I am never ill and of course, nothing became of it, because the CDC have a mindset that only vaccines and nothing else will be even considered and what hope has anyone got, when they can’t or won’t think outside the box – I mean this vaccine rubbish is so pointless – when salt does everything that nothing else does.
They say it has to be tested and confirmed by 3 experts and a study to discover its effectiveness in trials and the whole bit – yet the very same arguments occur for “the vaccine” which they don’t have – and Jenner back in 1779 came up with a vaccine type approach to curing Cow Pox which he tried on himself and that was OK, but that I have been doing exactly the same thing with my salt treatment, for longer than the past 25 years, is not. If that is not a double standard, then I don’t know what is!!
